IPSC Century Therapeutics Inc

249

$2.02

$0.00

(0.00%)

Today

Watchers	249
52-Wk Low	$2.00
52-Wk High	$11.95

Market Cap	$120.73M
Volume (M)	41,644.00
52-Wk High	$11.95
52-Wk Low	$2.00

Fundamentals

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines ConferenceGlobe Newswire • 3 days ago

PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...

Share to Feed

Century Therapeutics (NASDAQ:IPSC) Stock Rating Lowered by JPMorgan Chase & Co.Zolmax • about 1 month ago

Century Therapeutics (NASDAQ:IPSC Get Free Report) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating in a note issued to investors on Monday, MarketBeat.com reports. They currently have a $5.00 price objective on the stock, down from their previous ...

Century Therapeutics (NASDAQ:IPSC) Cut to Neutral at JPMorgan Chase & Co.Ticker Report • about 1 month ago

Century Therapeutics (NASDAQ:IPSC Get Free Report) was downgraded by analysts at JPMorgan Chase Co. from an overweight rating to a neutral rating in a...

Century Therapeutics (NASDAQ:IPSC) versus Genetic Technologies (NASDAQ:GENE) Financial AnalysisZolmax • about 1 month ago

Genetic Technologies (NASDAQ:GENE Get Free Report) and Century Therapeutics (NASDAQ:IPSC Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, ...

Century Therapeutics (NASDAQ:IPSC) and Genetic Technologies (NASDAQ:GENE) Financial ContrastTicker Report • about 1 month ago

Century Therapeutics (NASDAQ:IPSC Get Free Report) and Genetic Technologies (NASDAQ:GENE Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, ...

Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of "Buy" from BrokeragesZolmax • about 1 month ago

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC Get Free Report) have been given an average recommendation of Buy by the seven brokerages that are covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among ...

FY2023 EPS Estimates for Century Therapeutics, Inc. Boosted by Analyst (NASDAQ:IPSC)Zolmax • about 1 month ago

Century Therapeutics, Inc. (NASDAQ:IPSC Free Report) Stock analysts at Chardan Capital lifted their FY2023 earnings per share (EPS) estimates for shares of Century Therapeutics in a research note issued on Wednesday, August 9th. Chardan Capital analyst Y. Livshits now anticipates that the company ...

FY2023 EPS Estimates for Century Therapeutics, Inc. (NASDAQ:IPSC) Boosted by Chardan CapitalZolmax • about 2 months ago

Century Therapeutics, Inc. (NASDAQ:IPSC Free Report) Research analysts at Chardan Capital upped their FY2023 EPS estimates for shares of Century Therapeutics in a research note issued to investors on Wednesday, August 9th. Chardan Capital analyst Y. Livshits now anticipates that the company will ...

Head-To-Head Analysis: Century Therapeutics (NASDAQ:IPSC) versus Fennec Pharmaceuticals (NASDAQ:FENC)Zolmax • about 2 months ago

Century Therapeutics (NASDAQ:IPSC Get Free Report) and Fennec Pharmaceuticals (NASDAQ:FENC Get Free Report) are both small-cap medical companies, but which is the better investment...

Brokers Issue Forecasts for Century Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:IPSC)Ticker Report • about 2 months ago

Century Therapeutics, Inc. (NASDAQ:IPSC Free Report) Stock analysts at William Blair raised their Q3 2023 earnings per share (EPS) estimates for Century Therapeutics in a report released on Wednesday, August 9th. William Blair analyst S. Corwin now expects that the company will earn...